Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (ANIK) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
anik · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Anika Therapeutics, Inc. (ANIK) measures how much investors pay for each dollar of the company's trailing earnings. ANIK's current PE ratio of N/A is calculated by dividing its stock price of $14.60 by its TTM earnings per share of -$0.82.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%23.6x
MedianQ3 · 75%124.8x
Max
At N/A, ANIK's current P/E is lower than in 0% of its annual fiscal year readings over the past 15 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Anika Therapeutics, Inc.You ANIK | $194M | N/A | — | -$0.82 |
 Anixa Biosciences, Inc. ANIX | $84M | N/A | — | -$0.34 |
 Apyx Medical Corporation APYX | $209M | N/A | — | -$0.27 |
 Accuray Incorporated ARAY | $39M | N/A | — | -$0.02 |
 Anteris Technologies Global Corp. AVR | $344M | N/A | — | -$3.99 |
 LENSAR, Inc. LNSR | $68M | N/A | — | -$2.87 |
 Lucid Diagnostics Inc. LUCD | $101M | N/A | — | -$0.57 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.76 | — | |
2024-12-31 FY2024 | — | $-3.83 | — | |
2023-12-31 FY2023 | — | $-5.64 | — | |
2022-12-31 FY2022 | — | $-1.02 | — | |
2021-12-31 FY2021 | 124.82x | $0.29 | — | |
2020-12-31 FY2020 | — | $-1.69 | — | |
2019-12-31 FY2019 | 26.93x | $1.93 | +3.9% | |
2018-12-31 FY2018 | 25.93x | $1.30 | +5.0% | |
2017-12-31 FY2017 | 24.70x | $2.18 | +11.8% | |
2016-12-31 FY2016 | 22.09x | $2.22 | +19.2% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Anika Therapeutics, Inc. (ANIK) measures how much investors pay for each dollar of the company's trailing earnings. ANIK's current PE ratio of N/A is calculated by dividing its stock price of $14.60 by its TTM earnings per share of -$0.82.
Frequently asked questions
ANIK pe ratio · 6 questionsANIK's current PE ratio is N/A as of 2026-06-09, based on a stock price of $14.60 and TTM EPS of -$0.82. Data sourced from Financial Modeling Prep via ANIK's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Anika Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09